Proteomic insights into chronic anthracycline cardiotoxicity

Martin Stěrba1, Olga Popelová, Juraj Lenčo

  • 1Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic. sterbam@lfhk.cuni.cz

Insights

Chronic anthracycline cardiotoxicity, a chemotherapy side effect, damages heart mitochondria and proteins. This study reveals key molecular changes, offering insights for reducing heart failure risk.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiology

Background:

  • Chronic anthracycline cardiotoxicity is a serious, poorly understood complication of cancer chemotherapy.
  • Decades of research have not fully elucidated the molecular mechanisms underlying this heart failure.
  • Understanding these mechanisms is crucial for developing preventative or therapeutic strategies.

Purpose of the Study:

  • To gain integrative molecular insights into chronic anthracycline cardiotoxicity using a proteomic approach.
  • To identify key molecular alterations in the heart following anthracycline treatment.
  • To correlate proteomic changes with functional and morphological data.

Main Methods:

  • Anthracycline cardiotoxicity induced in rabbits using daunorubicin.
  • Left ventricular proteome analyzed via 2D-DIGE and MALDI-TOF/TOF.
  • Key findings validated by immunohistochemistry, qRT-PCR, and enzyme activity assays.

Main Results:

  • Significant alterations identified in mitochondrial proteins involved in oxidative phosphorylation, energy metabolism, and antioxidant defense.
  • Up-regulation and disorganization of the intermediate filament desmin, correlating with toxic damage.
  • Changes observed in myosin light chains, proteolytic machinery, chaperones, autophagy proteins, and extracellular matrix components.

Conclusions:

  • The study presents the first comprehensive proteomic signature of chronic anthracycline cardiotoxicity.
  • Identified molecular changes provide a deeper understanding of the basis of chemotherapy-induced heart failure.
  • Findings may facilitate the development of targeted interventions to mitigate cardiotoxicity.

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...